Pfizer Inc
NYSE : PFE$29.58−0.04%Oct 16 close
Financials
Consolidated Statements of Income
USD · reported units. Click a value to inspect its source.
| Reported line item | Jan 1, 2023 to Dec 31, 2023 (current) | Jan 1, 2022 to Dec 31, 2022 | Jan 1, 2021 to Dec 31, 2021 |
|---|---|---|---|
| Product revenues | |||
| Alliance revenues | |||
| Total revenues | |||
| Cost of sales | |||
| Selling, informational and administrative expenses | |||
| Research and development expenses | |||
| Acquired in-process research and development expenses | |||
| Amortization of intangible assets | |||
| Restructuring charges and certain acquisition-related costs | |||
| Other (income)/deductionsnet | |||
| Income from continuing operations before provision/(benefit) for taxes on income | |||
| Provision/(benefit) for taxes on income | |||
| Income from continuing operations | |||
| Discontinued operationsnet of tax | |||
| Net income before allocation to noncontrolling interests | |||
| Less: Net income attributable to noncontrolling interests | |||
| Net income attributable to Pfizer Inc. common shareholders | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)USD / share | |||
| Discontinued operationsnet of tax (in dollars per share)USD / share | |||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share)USD / share | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)USD / share | |||
| Discontinued operationsnet of tax (in dollars per share)USD / share | |||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share)USD / share | |||
| Weighted-average sharesbasicShares | |||
| Weighted-average sharesdilutedShares |
25 line items · 3 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.